Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt
(NASDAQ : GALTU)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading GALTU News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.28%166.981.2%$750.32m
INCYIncyte Corporation
-0.52%140.551.7%$622.47m
GILDGilead Sciences, Inc.
-0.32%67.611.0%$592.31m
CELGCelgene Corporation
0.09%123.481.0%$512.60m
BIIBBiogen Inc.
0.14%278.251.3%$453.04m
REGNRegeneron Pharmaceuticals, Inc.
-0.20%368.392.1%$317.11m
KITEKite Pharma, Inc.
-1.38%75.3318.8%$207.24m
ALXNAlexion Pharmaceuticals, Inc.
0.13%120.231.6%$206.05m
TSROTESARO, Inc.
0.07%155.8916.1%$177.57m
ESPREsperion Therapeutics, Inc.
0.43%39.1818.7%$165.22m
ILMNIllumina, Inc.
-0.36%167.183.7%$164.64m
AUPHAurinia Pharmaceuticals Inc.
-0.35%8.506.3%$148.24m
CLVSClovis Oncology, Inc.
3.86%69.7717.5%$146.91m
VRTXVertex Pharmaceuticals Incorporated
0.22%90.242.2%$135.26m
GBTGlobal Blood Therapeutics Inc
1.84%38.7011.9%$106.43m

Company Profile

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.